I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

Immuno-oncology (IO) drugs or cancer therapeutics represent one of the most promising areas of medical innovation in the next ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.